Fabrinet Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Fabrinet (FN) on December 19, 2024. The filing discloses an amendment to the employment agreement of Dr. Harpal Gill, the Company's President and Chief Operating Officer (COO).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes
The primary material change is the execution of an Amended and Restated Offer Letter for Dr. Harpal Gill, effective December 19, 2024. Key terms include:
- Compensation: Confirms an annual base salary of $1,100,000 and an annual cash bonus opportunity of at least 95% of base salary.
- Role Transition: If a new COO is appointed, Dr. Gill will remain as President and is tasked with recruiting and training a successor to commence by the earlier of December 31, 2027, or six months following a notice period.
- Termination Notice: Employment may be terminated by either party with one year's written notice, or immediately for cause.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or general risk factors. The primary contingency detailed is the severance package triggered by termination without good cause, death, or disability, or resignation. Benefits include:
- A lump sum payment equal to one month's base salary multiplied by total years of employment, plus earned unpaid bonuses and two times the cost of 12 months of COBRA coverage.
- Acceleration of 100% of unvested Restricted Stock Unit (RSU) awards (excluding performance-based awards).
- Continued eligibility for performance-based equity awards subject to performance goals.
- Continued tax equalization benefits for the termination year and the following calendar year.
Investor Verification Checklist
- Verify the total years of Dr. Gill's employment to calculate the potential lump-sum severance multiplier.
- Review the specific performance objectives for the 95% bonus opportunity as established by the Compensation Committee.
- Confirm the current status of unvested RSU and performance-based equity awards held by Dr. Gill.
- Monitor for the appointment of a successor COO and the associated timeline for transition.